. 2006 Jan;96(1):114–119. doi: 10.2105/AJPH.2004.056796

TABLE 2—

Cost-Effectiveness and Sensitivity Analyses Without Free VCT, With a Free VCT Campaign, and With Sustained Free VCT

	No Free VCT						Free VCT Campaign						Sustained Free VCT
	Number Treated	New Diagnoses	Infections Averted	Cost Per Infection Averted^a	DALYs Gained	Cost Per DALY, US $	Number Treated	New Diagnoses	Infections Averted	Cost Per Infection Averted	DALYs Gained	Cost Per DALY, US $	Number Treated	New Diagnoses	Infections Averted	Cost Per Infection Averted	DALYs Gained	Cost Per DALY, US $
	Prevention
HIV prevalence
Observed (16.7%)	. . .	. . .	67.9	169.69	1321	8.72	. . .	. . .	131.0	105.12	2549	5.40	. . .	. . .	275.0	91.89	5352	4.72
Low (8%)	. . .	. . .	40.0	288.04	778	14.80	. . .	. . .	77.2	178.47	1502	9.17	. . .	. . .	162.0	156.00	3152	8.02
High (25%)	. . .	. . .	95.0	121.24	1848	6.23	. . .	. . .	183.3	75.12	3567	3.86	. . .	. . .	384.9	65.66	7490	3.37
	New diagnoses
HIV prevalence
Observed (16.7%)	. . .	161.4	. . .	. . .	. . .	. . .	. . .	311.3	. . .	. . .	. . .	. . .	. . .	653.8	. . .	. . .	. . .	. . .
Low (8%)	. . .	77.3	. . .	. . .	. . .	. . .	. . .	149.1	. . .	. . .	. . .	. . .	. . .	313.2	. . .	. . .	. . .	. . .
High (25%)	. . .	241.5	. . .	. . .	. . .	. . .	. . .	466.0	. . .	. . .	. . .	. . .	. . .	978.8	. . .	. . .	. . .	. . .
	Antiretroviral treatment^b
Rates of treatment
Medium (30%)	48.4	. . .	. . .	. . .	48.4	420.00^c	93.4	. . .	. . .	. . .	93.4	420.00	196.1	. . .	. . .	. . .	196.1	420.00
Low (10%)	16.1	. . .	. . .	. . .	16.1	420.00^c	31.1	. . .	. . .	. . .	31.1	420.00	65.4	. . .	. . .	. . .	65.4	420.00
High (50%)	80.7	. . .	. . .	. . .	80.7	420.00^c	155.6	. . .	. . .	. . .	155.6	420.00	326.9	. . .	. . .	. . .	326.9	420.00
	Tuberculosis prophylaxis^b
Rates of treatment
Medium (50%)	80.7	. . .	. . .	. . .	12.1	166.67^d	155.6	. . .	. . .	. . .	23.3	166.67	326.9	. . .	. . .	. . .	49.0	166.67
Low (30%)	48.4	. . .	. . .	. . .	7.3	166.67^d	93.4	. . .	. . .	. . .	14.0	166.67	196.1	. . .	. . .	. . .	29.4	166.67
High (70%)	112.9	. . .	. . .	. . .	16.9	166.67^d	217.9	. . .	. . .	. . .	32.7	166.67	457.7	. . .	. . .	. . .	68.6	166.67
	Summary^b
Scenario
Medium treatment	. . .	. . .	. . .	. . .	1381.4	24.52	. . .	. . .	. . .	. . .	2666.0	21.34	. . .	. . .	. . .	. . .	5,597.2	20.69
Low treatment	. . .	. . .	. . .	. . .	1344.3	14.51	. . .	. . .	. . .	. . .	2594.4	11.25	. . .	. . .	. . .	. . .	5,446.9	10.58
High treatment	. . .	. . .	. . .	. . .	1418.5	34.00	. . .	. . .	. . .	. . .	2737.6	30.90	. . .	. . .	. . .	. . .	5,747.6	30.28

Note. VCT = voluntary counseling and testing; DALY = disability-adjusted life year.

^aBased on previous estimates in Tanzania.2

^b With an observed HIV infection prevalence of 16.7%.

^cAssumes cost for antiretroviral therapy of $35 per month and does not include cost for monitoring and care.

^dBased on an estimated cost of $25 for 6 months of preventive therapy.15